JP2014527397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527397A5 JP2014527397A5 JP2014516320A JP2014516320A JP2014527397A5 JP 2014527397 A5 JP2014527397 A5 JP 2014527397A5 JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014527397 A5 JP2014527397 A5 JP 2014527397A5
- Authority
- JP
- Japan
- Prior art keywords
- chokα
- expression level
- patient
- sample
- reference value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 238000000338 in vitro Methods 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102100031065 Choline kinase alpha Human genes 0.000 claims 3
- 101710106334 Choline kinase alpha Proteins 0.000 claims 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 239000013610 patient sample Substances 0.000 claims 3
- 229940122255 Microtubule inhibitor Drugs 0.000 claims 2
- 239000004052 folic acid antagonist Substances 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382211 | 2011-06-20 | ||
| EP11382211.8 | 2011-06-20 | ||
| US201161507833P | 2011-07-14 | 2011-07-14 | |
| US61/507,833 | 2011-07-14 | ||
| EP11382294.4 | 2011-09-16 | ||
| EP11382294 | 2011-09-16 | ||
| PCT/EP2012/061790 WO2012175537A1 (en) | 2011-06-20 | 2012-06-20 | Method for predicting the clinical response to chemotherapy in a subject with cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014527397A JP2014527397A (ja) | 2014-10-16 |
| JP2014527397A5 true JP2014527397A5 (enExample) | 2015-08-13 |
Family
ID=47422050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014516320A Pending JP2014527397A (ja) | 2011-06-20 | 2012-06-20 | 癌患者の化学療法に対する臨床応答を予測する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150004252A1 (enExample) |
| EP (1) | EP2721174A1 (enExample) |
| JP (1) | JP2014527397A (enExample) |
| KR (1) | KR20140047664A (enExample) |
| CN (1) | CN103687964A (enExample) |
| AU (1) | AU2012274156A1 (enExample) |
| BR (1) | BR112013032857A2 (enExample) |
| CA (1) | CA2840129A1 (enExample) |
| MX (1) | MX2013015286A (enExample) |
| RU (1) | RU2014101492A (enExample) |
| WO (1) | WO2012175537A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| US20170305861A1 (en) * | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
| EP3487857B1 (en) * | 2016-07-25 | 2021-09-01 | Nerviano Medical Sciences S.r.l. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| CN110494570A (zh) | 2017-03-29 | 2019-11-22 | 中美冠科生物技术（太仓）有限公司 | 确定癌症对卡仑尼替星敏感性的系统和方法 |
| CN107050668B (zh) * | 2017-06-09 | 2020-03-31 | 南京医科大学第一附属医院 | 基于云处理的放疗效果预测方法 |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2237332B1 (es) | 2004-01-14 | 2006-11-01 | Consejo Sup. Investig. Cientificas | Derivados de piridinio y quinolinio. |
| CN102228689A (zh) * | 2005-04-13 | 2011-11-02 | 科学研究高等机关 | 鉴定用于癌症治疗的化合物的体外方法 |
| GB0519405D0 (en) * | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
| EP2316970A2 (en) * | 2008-07-04 | 2011-05-04 | Traslational Cancer Drugs Pharma, S.L. | Methods for the treatment and diagnosis of cancer |
| EP2324123B1 (en) | 2008-09-10 | 2016-07-20 | Rutgers, The State University of New Jersey | IMAGING INDIVIDUAL mRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBES |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
-
2012
- 2012-06-20 CA CA2840129A patent/CA2840129A1/en not_active Abandoned
- 2012-06-20 EP EP12730874.0A patent/EP2721174A1/en not_active Withdrawn
- 2012-06-20 MX MX2013015286A patent/MX2013015286A/es not_active Application Discontinuation
- 2012-06-20 RU RU2014101492/10A patent/RU2014101492A/ru not_active Application Discontinuation
- 2012-06-20 BR BR112013032857A patent/BR112013032857A2/pt not_active IP Right Cessation
- 2012-06-20 AU AU2012274156A patent/AU2012274156A1/en not_active Abandoned
- 2012-06-20 KR KR1020147001560A patent/KR20140047664A/ko not_active Withdrawn
- 2012-06-20 US US14/128,369 patent/US20150004252A1/en not_active Abandoned
- 2012-06-20 CN CN201280035399.6A patent/CN103687964A/zh active Pending
- 2012-06-20 JP JP2014516320A patent/JP2014527397A/ja active Pending
- 2012-06-20 WO PCT/EP2012/061790 patent/WO2012175537A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | NEAT 1: A novel cancer‐related long non‐coding RNA | |
| Zhang et al. | MicroRNAs: a new key in lung cancer | |
| Liu et al. | Biomarkers for EMT and MET in breast cancer: An update | |
| Chen et al. | Predicting distant metastasis and chemoresistance using plasma miRNAs | |
| Yu et al. | The role of mi RNA s in cutaneous squamous cell carcinoma | |
| JP2014527397A5 (enExample) | ||
| Drygin et al. | Targeting the nucleolus for cancer-specific activation of p53 | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| Yan et al. | Expression and significance of circulating microRNA-31 in lung cancer patients | |
| Li et al. | Clinical significance of blood‑based miRNAs as biomarkers of non‑small cell lung cancer | |
| Xia et al. | EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo | |
| JP2014533960A5 (enExample) | ||
| Sheng et al. | MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma | |
| Chen et al. | Brain metastases completely disappear in non-small cell lung cancer using hydrogen gas inhalation: A case report | |
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target | |
| Liu et al. | Effect of miR-21 on apoptosis in hepatoblastoma cell through activating ASPP2/p38 signaling pathway in vitro and in vivo | |
| Robinson et al. | The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma | |
| CN103725779A (zh) | 一种非小细胞肺癌早期诊断血清/血浆miRNA标志物及其应用 | |
| Bai et al. | Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer | |
| RU2014101492A (ru) | Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак | |
| Ondracek et al. | Global microRNA expression profiling identifies unique microRNA pattern of radioresistant glioblastoma cells | |
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| Liang et al. | Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines | |
| Fang et al. | The expression of microRNA-340 and cyclin D1 and its relationship with the clinicopathological characteristics and prognosis of lung cancer | |
| EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли |